Results 161 to 170 of about 153,232 (265)

Percutaneous Transaxillary Access for Large‐Bore Cardiovascular Interventions: Evidence, Technique, and Complication Management

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Percutaneous transaxillary access is an established alternative to transfemoral large‐bore arterial access for transcatheter structural heart interventions and mechanical circulatory support (MCS). Although useful for overcoming hostile iliofemoral anatomy and providing prolonged support and patient mobilization in case of MCS, the axillary ...
Gioel Gabrio Secco   +9 more
wiley   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri   +12 more
wiley   +1 more source

ANEURYSMS OF THE MIDDLE CEREBRAL ARTERY

open access: yesAnnals of Surgery, 1953
E, CAMPBELL, C W, BURKLUND
openaire   +3 more sources

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao   +27 more
wiley   +1 more source

Home - About - Disclaimer - Privacy